Comparative Pharmacology
Head-to-head clinical analysis: DILATRATE SR versus ISOSORBIDE MONONITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILATRATE SR versus ISOSORBIDE MONONITRATE.
DILATRATE-SR vs ISOSORBIDE MONONITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DILATRATE-SR (isosorbide dinitrate) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels. This leads to venous and arterial dilation, reducing preload and afterload.
Isosorbide mononitrate is an organic nitrate that acts as a vasodilator. It is metabolized to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells. This leads to dephosphorylation of myosin light chains and relaxation of smooth muscle, resulting in dilation of peripheral arteries and veins. Venodilation reduces preload, while arterial dilation reduces afterload, decreasing myocardial oxygen demand.
40 mg orally twice daily, 6–8 hours apart, as sustained-release formulation. Maximum dose: 160 mg twice daily.
20 mg orally twice daily, with the two doses given 7 hours apart to maintain low nitrate-free interval.
None Documented
None Documented
Clinical Note
moderateIsosorbide mononitrate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Isosorbide mononitrate."
Clinical Note
moderateIsosorbide mononitrate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Isosorbide mononitrate."
Clinical Note
moderateIsosorbide mononitrate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Isosorbide mononitrate."
Clinical Note
moderateIsosorbide mononitrate + Fluconazole
Terminal half-life is 4-6 hours, but clinical effect lasts 8-12 hours due to sustained-release formulation.
Terminal half-life: 4–5 hours; clinical context: allows twice-daily dosing for sustained antianginal effect.
Renal excretion of inactive metabolites accounts for approximately 60-80% of clearance, with biliary/fecal elimination contributing 20-40%.
Renal: ~93% (as metabolites, primarily isosorbide and glucuronides); fecal: ~2%; biliary: negligible.
Category C
Category A/B
Nitrate
Nitrate
"The metabolism of Fluconazole can be decreased when combined with Isosorbide mononitrate."